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Abstract 
Background: Active consideration of effective medications to treat alcohol use disorder (AUD) is a consensus stand-
ard of care, yet knowledge and use of these medications are very low across diverse settings. This study evaluated the 
overall effectiveness a multifaceted academic detailing program to address this persistent quality problem in the US 
Veterans Health Administration (VHA), as well as the context and process factors that explained variation in effective-
ness across sites.
Methods: An interrupted time series design, analyzed with mixed-effects segmented logistic regression, was used 
to evaluate changes in level and rate of change in the monthly percent of patients with a clinically documented AUD 
who received naltrexone, acamprosate, disulfiram, or topiramate. Using data from a 20 month post-implementation 
period, intervention sites (n = 37) were compared to their own 16 month pre-implementation performance and 
separately to the rest of VHA.
Results: From immediately pre-intervention to the end of the observation period, the percent of patients in the 
intervention sites with AUD who received medication increased over 3.4 % in absolute terms and 68 % in relative 
terms (i.e., 4.9–8.3 %). This change was significant compared to the pre-implementation period in the intervention 
sites and secular trends in control sites. Sites with lower pre-implementation adoption, more person hours of detail-
ing, but fewer people detailed, had larger immediate increases in medication receipt after implementation. The aver-
age number of detailing encounters per person was associated with steeper increases in slope over time.
Conclusions: This study found empirical support for a multifaceted quality improvement strategy aimed at increas-
ing access to and utilization of pharmacotherapy for AUD. Future studies should focus on determining how to 
enhance the programs effects, especially in non-responsive locations.
Keywords: Pharmacotherapy, Medication assisted treatment, Alcohol use disorder, Quality improvement, 
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Background
Both psychosocial and pharmacological treatments 
for alcohol use disorder (AUD; formerly abuse and 
dependence) have been found to be effective in reducing 
symptoms and improving functioning in diverse patient 
populations [1–5]. In the United States (US), 16.6 million 
people over 18 years of age in 2013 (7.0 %) met diagnostic 
criteria for AUD yet only 1.3 million (7.8 %) received any 
formal treatment [6]. Even within the Veterans Health 
Administration (VHA), the largest integrated healthcare 
system in the US with a well-developed system of 220 
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specialty addiction programs, the treatment rate among 
the roughly 400,000 patients clinically diagnosed with 
an AUD in fiscal year 2013 (6.8 % of all VA patients) was 
only 32  %. Clearly, developing and evaluating strategies 
to improve access to and engagement in effective treat-
ments for AUD is of utmost importance [7].
Several medications are US Federal Drug Administra-
tion (FDA)-approved for the treatment of AUD, and/or 
have support of effectiveness from high-quality meta-
analysis, namely naltrexone, acamprosate, disulfiram, 
and topiramate. These medications can be prescribed 
and managed in diverse clinical settings [1–3], allowing 
patients more options regarding the type and location of 
their AUD treatment, thus potentially increasing access 
and treatment engagement. However among both pro-
viders and patients, knowledge and use of these medi-
cations to treat AUD in the US is very low and variable 
[8–13]. In VHA, low and variable utilization of these 
medications for AUD persists even though all of them are 
on the national formulary and supported by VHA clini-
cal practice guidelines and policies [14]. The VA Uniform 
Mental Health Services Handbook states that evidence-
based pharmacotherapy is to be offered and available to 
all patients diagnosed with AUD if not medically con-
traindicated [14]. However, among the VHA patients 
diagnosed with AUD in FY13, only 5.8  % received evi-
denced-based pharmacotherapy. Even among Veterans 
seeking treatment in one of VHA’s specialty addiction 
treatment programs, only 9.9  % received medication 
treatment for AUD [9, 15].
Not only is the overall rate of medication receipt low 
for patients with AUD in VHA, there is substantial facil-
ity-level variability [9, 15]. The rate of pharmacotherapy 
for AUD among Veterans who received SUD specialty 
care in FY13 ranged from 0 to 21 % across facilities. Low 
prescribing rates and significant variation across facili-
ties suggests that significant gaps exist in patients’ access 
to these medications, especially in some locations. The 
existence of facilitative formulary and clinical policies, as 
well as near real time performance monitoring [16], may 
be necessary but has not been sufficient to adequately 
improve performance on this standard of care.
To address this substantial and persistent quality gap, 
VHA’s Office of Patient Care Services funded the Aca-
demic Detailing for Mental Health Initiatives Program 
that developed and executed campaigns to improve 
implementation of pharmacological treatment for several 
mental health and addictive disorders, including tobacco 
dependence, schizophrenia, depression, posttraumatic 
stress disorder, and most recently, and the focus of this 
study, AUD. In 2013, this quality improvement program 
sent clinical pharmacy specialists (“academic detailers”) 
to clinical settings within two western VHA networks. 
The academic detailers strove to educate, motivate, and 
enable key health care providers to identify and address 
the spectrum of hazardous alcohol use, especially to 
facilitate more active consideration of pharmacologi-
cal treatment options for AUD. The effectiveness of the 
AUD campaign of the Academic Detailing Program, and 
the context and process factors that might be associated 
with its effectiveness, have not been rigorously evaluated. 
Thus, the goal of the current study is to evaluate this mul-
tifaceted implementation strategy as means to increase 
utilization of pharmacotherapy for AUD, as well as to 
provide data that might inform and enhance the ongo-
ing expansion of academic detailing programming across 
VHA.
Methods
The academic detailing program
The primary goal of the Academic Detailing AUD Cam-
paign was to increase the proportion of patients with 
AUD who were receiving treatment with naltrexone, 
acamprosate, disulfiram, or topiramate. Simple aca-
demic detailing interventions have been shown to have 
small but significant effects on prescribing practices [17]. 
However the approach evaluated here was more elabo-
rate and multifaceted than typical academic detailing or 
educational outreach interventions [17]. Aspects of the 
program were similar to an external facilitation model 
where barriers and problems are iteratively identified and 
addressed in real time [18, 19]. No firm standard existed 
for the intended number of detailing encounters per site. 
However given the positive relationship between number 
of educational outreach visits by pharmaceutical repre-
sentatives and sales [20], multiple visits were attempted, 
especially in sites with persistent non-response. As such, 
this program was akin to a hybrid academic detailing/
audit and feedback/external facilitation intervention 
[19, 21]. Another unique and key feature of the program 
was the implementation of a real-time informatics dash-
board so clinicians and detailers could identify patients 
who might be candidates for the medications (e.g., recent 
diagnosis of AUD, not currently receiving medications), 
as well as to assess site-level performance. Audit and 
feedback has been shown to be more effective when base-
line performance is low, when feedback is given more 
than once, is given verbally and in writing, and when 
coupled with support and a clear action plan [17], which 
were all features of this program.
Table  1 outlines the major activities of the program. 
After Identifying leadership partners and establishing 
buy-in (Step 1), detailers identified clinical staff with a 
high volume of patients with AUD (Step 2), and detail-
ing encounters were requested with these priority clini-
cal staff (Step 3). The goal then was to build rapport and 
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engage staff in discussions about evidence-based medi-
cations and other AUD treatment options (Step 4), itera-
tively identify barriers (Step 5), and provide additional 
resources including a real-time audit and feedback and 
case finding tool (Steps 6 and 7). Importantly, the detailers 
sought a commitment from staff to try to increase use of 
evidence-based medications for AUD (Step 8), and con-
tinued to monitor and problem solve if needed (Step 9).
Academic detailers were recruited and selected with 
preference for previous training experience in mental 
health, board certification as pharmacotherapy special-
ists, post graduate residency training, and strong com-
munication skills assessed during interview process. Due 
to the clinical service content of the detailing encounters, 
candidates were sought who had provided direct patient 
care as part of their previous professional experience 
with prescribing authority under a scope of practice. The 
Department of Veteran’s Affairs then contracted Alosa 
Foundation, a nonprofit organization that develops and 
implements academic detailing programs to improve 
prescribing, to provide a basic skills course in academic 
detailing to the six clinical pharmacists who were selected 
for VA facilities in California, Nevada and the Pacific 
Islands. In addition to Academic Detailing Basic Skills 
workshop, Motivational Interviewing training, adapted 
for use within the context of a provider outreach visit as 
opposed to a clinical treatment with a patient population, 
was another important aspect of detailer training. Cam-
paign specific training on AUD was conducted through 
virtual seminars and one 3-day face-to-face conference, 
in which subject matter experts assisted in structuring 
the AUD campaign timeline and targeted goals.
From April to December 2013, the AUD campaign of 
the Academic Detailing Program was implemented in two 
western VA networks, including over 37 medical centers 
and community-based outpatient clinics. Detailing sessions 
included predominantly in-person one-on-one sessions, 
in-person group sessions, and educational in-service ses-
sions, with additional follow-up conducted by email, tel-
econference, and telephone. A wide variety of staff received 
detailing encounters including psychologists, psychiatrists, 
nurses, social workers, clinical pharmacists, primary physi-
cians, clinical managers and other administrators.
Analysis of overall effectiveness
We evaluated the overall effectiveness of the program 
using a multi-site, interrupted time series design. The 
main outcome for the evaluation was the monthly pro-
portion of patients with a clinical encounter in which 
AUD was documented who filled a prescription for 
one of the targeted medications: naltrexone, acampro-
sate, disulfiram, or topiramate. Intervention sites had 
16 months of baseline pharmacy data prior to their first 
detailing contact, and were observed for 20  months 
thereafter. Mixed-effects segmented logistic regression 
[22] was used to estimate the parameters for the pre- and 
post-implementation segments, with random effects to 
account for the nesting of patients within months within 
sites. The first model, using the intervention sites as their 
own controls, compared the change in level from Month 
16 in the pre-implementation period to the immediate 
post-implementation in Month 17 (i.e., “gap”) as well as 
the change in slope from the pre-implementation to the 
post-implementation period. In the second model, we 
Table 1 Features and methods of academic detailing for mental health initiatives program
Identify leadership partners and establish buy-in: Meeting were requested and conducted with key clinical and pharmacy leadership to explain the 
goals and methods of the initiative, as well as address concerns and high-level barriers
Identify clinical staff with a high volume of patients with AUD in both primary care and mental health/addiction specialty care: using administrative 
data, the program identified staff with large numbers of AUD patients
Request detailing encounters with these priority providers, citing the previously established leadership support and enthusiasm
Build relationships with priority providers, engaging them in discussions about evidence-based medications and other practices (e.g., brief intervention 
for risky drinking): the goal was repeated visits to establish rapport and perceived value by the clinicians who received the resources and services
Explore barriers to prescribing the medications and applying the practices
 Examine and address knowledge and beliefs about the supporting evidence
 Address knowledge and misunderstandings about policies and scope of competence (e.g., belief that policy prohibits primary care clinicians from 
prescribing naltrexone or other AUD medications)
 Identify and problem-solve structural or logistical barriers (e.g., local policy or practice, staffing medication management visits.)
Introduce the providers to additional resources and tools including patient education tools, and pocket cards with FAQs
Introduce real-time, electronic medical record-integrated audit and feedback tools to identify actionable patients
Seek a commitment from the clinician to try to increase prescribing of the medications
Monitor progress and check back periodically for additional education, barrier identification, problem solving, and feedback. Monitor clinical targets 
(e.g., the number of patients receiving medications for AUD) and clinician use of the informatics tools, especially the case-finding dashboards. If the 
targeted prescribing behavior was unaffected, the next detailing session would again explore barriers, problem solve, and motivate clinicians
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compared the pre-post gap and changes in slope in the 
intervention sites to non-intervention control sites to 
ensure that the observed effects were not due to secular 
trends in the rest of VHA.
Context and process factors
We then calculated and described facility-level vari-
ability in effectiveness, operationalized as the immedi-
ate pre-post implementation gaps and changes in slope. 
Then, we examined the context and process factors (i.e., 
moderators and mediators) that were associated with 
this variability and for which data were available from 
administrative sources or from Academic Detailing Pro-
gram encounter logs. The main facility-level moderator 
examined was the pre-implementation rate of receipt of 
medications for AUD, calculated from VHA pharmacy 
data. Candidate mediators included total person-hours 
of detailing, total number of health care providers con-
tacted by the program, and number of unique detailing 
sessions, all sourced from program encounter logs. We 
did not examine the effects of detailing encounter type 
(group vs. individual) or provider type on effectiveness 
due to substantial within-site variability on these factors. 
All candidate predictors were entered into the mixed-
effect regression model described above, restricted to 
sites with detailing encounters, and interacted with the 
immediate gap and change in slope.
Results
Overall effectiveness in sites with detailing encounters
For simplicity of interpretation, we converted the mixed-
effects segmented logistic regression estimates into 
percents and graphically represented them in Fig.  1. As 
represented by the red trajectory in Fig.  1, the average 
proportion of patients with AUD who filled a prescrip-
tion for naltrexone (oral or injectable), acamprosate, 
disulfiram, or topiramate in the 37 intervention sites was 
4.56 % at baseline. The pre-implementation slope in the 
intervention sites was not significantly different than 
zero and increased to 4.96  % by Month 16. The gap of 
1.04–6.00 % between Month 16 and 17 in the interven-
tion sites was significant (p < .0001). Also, the pre-to-post 
increase in slope in the intervention sites compared to 
the pre-implementation slope was significantly positive 
(p  <  .0001), with the proportion of patients with AUD 
receiving medication increasing to 8.32 % by the end of 
Month 36. Thus from immediately pre-intervention to 
the end of the observation period (Month 16–Month 36), 
the percent of patients with AUD who received medica-
tion increased 3.36  % in absolute terms and 67.77  % in 
relative terms.
Comparing medication trends in implementation 
and control sites
To check that these changes did not just mimic secular 
trends in the rest of VHA, we fitted a model that explic-
itly compared the four parameters in the intervention 
sites to the same parameters in all other VA sites. As rep-
resented by the black line in Fig. 1, at baseline in the rest 
of VHA, 6.01  % of patients with AUD filled a prescrip-
tion for one of the medications, a proportion significantly 
higher than the intervention sites. The slope for the rest 
of VHA in the pre-intervention period was not signifi-
cantly different than zero and increased to 6.67 % by the 
Fig. 1 Effects of academic detailing program implemented in 37 VHA sites compared to secular trend in rest of VHA. The red segments represent 
the intervention sites and the black segments represent the control sites
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end of Month 16. The gap of −0.09 % between Month 16 
and 17 in the rest of VHA to 6.58 % was slightly negative. 
The slope in the post-implementation period was slightly 
more positive than the pre-implementation period for 
the rest of VHA, ending at 6.90 % by the end of Month 
36. Both the immediate gap and change in slope were sig-
nificantly less than the intervention sites (p values <.001). 
Thus from Month 16 to Month 36 in the rest of VHA, the 
rate of medication receipt increased over 0.23 % in abso-
lute terms and 3.45 % in relative terms.
Context and process factors associated with program 
effects
In addition to these overall effects, significant variability 
among the 37 sites in the effects of the Academic Detail-
ing Program were found, with some sites having much 
bigger or smaller gaps and changes in slope than the 
overall average. Figure 2 shows the variation in the imme-
diate post-implementation gaps for all 37 sites. Although 
the average gap was just over 1 %, it ranged from −1.69 
to 2.14  %. The changes in slopes from the pre- to post-
implementation period also varied, ranging from −0.55 
to 0.08.
We then examined moderators and mediators that 
might explain variation in gaps and/or changes in slopes, 
as indicated by significant interaction terms in the 
mixed-effects segmented logistic regression. Descrip-
tive statistics for these variables are presented in Table 2. 
Sites with lower pre-implementation adoption (i.e., lower 
proportion of patients receiving medications) had larger 
immediate increases in medication receipt after imple-
mentation (95 % confidence interval for interaction odds 
ratio 0.004–0.1114), as did sites with more person hours 
of detailing (95 % confidence interval for interaction odds 
ratio 1.00001–1.000187), but fewer people detailed (95 % 
confidence interval for interaction odds ratio 0.9904–
0.9989). The average number of detailing encounters per 
person detailed was associated with steeper increases in 
slope over time (95 % confidence interval for interaction 
odds ratio 1.067–1.119).
Discussion
In this study, we evaluated a multifaceted academic 
detailing program aimed at addressing a serious and per-
sistent problem in healthcare quality—under-utilization 
of medications in the treatment of AUD. Despite strong 
evidence of clinical effectiveness of these medications, 
clinical and quality managers have thus far lacked evi-
dence-based quality improvement strategies to increase 
access and utilization. Using a rigorous quasi-experi-
mental design, we found that implementation of the Aca-
demic Detailing Program for AUD was associated with 
an overall immediate gap up in medication receipt as well 
a significant increase in the slope of adoption over time. 
From pre-intervention to the end of the follow-up period, 
the rate of medication receipt in the intervention sites 
increased approximately 3.4 % in absolute terms and 68 % 
in relative terms (i.e., 4.9–8.3 %). Although the interven-
tion sites overall had lower levels of utilization at baseline 
compared to the rest of VHA, levels of utilization in the 
intervention sites were higher by the end of the observa-
tion period. Extrapolating this effect to the entire VHA 
would mean that over 11,000 additional patients with 
AUD would receive these effective medications. To our 
knowledge, this is the first quality improvement strategy 
focused on increasing access to AUD medications to be 
implemented on a large scale and shown to be effective 
overall.
Although the Academic Detailing Program increased 
prescribing of medications for treatment of AUD over-
all, the effect varied substantially across the intervention 
sites. In many sites, there was no improvement or even 
reductions in prescription fills. In an effort to explain 
some of this variability, we found that initially low per-
forming facilities tended to improve the most. This result 
is encouraging and instructive. Although one might 
argue that those with lower baseline performance were 
more likely to improve due to regression to the mean 
[23], it is common in healthcare quality efforts for high 
performance sites to improve more than initially low per-
forming sites. Also, facilities that received more detail-
ing sessions and fewer people detailed tended to have 
Fig. 2 Variation in percent change in patients with AUD receiving 
medications in month following implementation
Table 2 Descriptive statistics of  site-level moderators 
and mediators of effectiveness
Variables Mean (SD) Range
Percent of AUD patients receiving medications 4.31 (2.54) 0–9.3
Person hours of detailing 26.63 (59.30) 0.15–330
Unique staff with detailing contact 31.76 (60.04) 1–325
Average encounters per detailed provider 1.12 (0.19) 1–1.8
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the greatest initial improvement (biggest immediate gap) 
while larger increases in the slope of utilization over time 
were experienced in facilities that had a higher aver-
age number of detailing encounters per detailed person. 
In general, these results support the notion that more 
detailing produces more positive change, and suggests 
that perhaps focusing on a few key prescribers up front 
creates an immediate bump in prescribing while broader 
detailing encourages sustained growth in prescribing.
Several questions are left unanswered by this inves-
tigation. First, there were many aspects of the detailing 
encounters for which data were unavailable, including 
prior knowledge level of the target clinician as well as skill 
and experience of the detailer. Many facilities received 
detailing encounters from multiple detailers making the 
direct examination of detailer effects difficult. Also, one 
aspect of detailer skill and potential impact is the ability 
to secure initial meetings with facility staff. We had data 
on completed detailing encounters but not encounter 
requests. These are important limitations that should be 
addressed in future implementations and evaluations. 
Second, data on use of the informatics tools was not ana-
lyzed. Qualitative interviews with detailers and detailed 
clinicians might have helped explain why sites varied in 
response to the Academic Detailing Program, and may 
have provided perspectives and data that could be used 
to refine the program. Third, the analyses were based 
on filled prescriptions not on written prescriptions, for 
which no data were available. We expect the impact of 
this limitation to be minimal because we have no rea-
son to believe that reliance on outside pharmacies or the 
proportion of unfilled prescriptions would be different 
in the pre and post implementation periods. Fourth, the 
campaign also sought to improve rates of screening, brief 
intervention, and referral to specialty treatment, data for 
which was unavailable for evaluation. Fifth, sustainment 
of effects after the program stopped was not examined. 
Sixth, data on cost of the intervention was not collected, 
precluding any budget impact or other economic analy-
ses. Finally, long-term sustainment or emergence of 
effects after the detailing encounters stop were not evalu-
ated but should be investigated in future analyses.
Conclusions
Even with these limitations and caveats, this study is 
perhaps the first to find empirical support for a multi-
faceted quality improvement strategy aimed at increas-
ing access to and utilization of effective medications in 
the treatment of AUD. Following the conclusion to this 
western VHA regional pilot for Academic Detailing for 
Mental Health Initiatives, in March 2015 VHA leader-
ship requested the 21 regional networks to develop aca-
demic detailing programming to impact two other key 
medication safety quality improvement programs in 
VHA, the Opioid Safety Initiative and the Psychotropic 
Drug Safety Initiative. Future studies should rigorously 
evaluate the program’s effects on other quality improve-
ment targets, focus on determining how to enhance 
the program effects, especially in sites where effects are 
weak. It is possible that less expensive and less labor 
intensive strategies would be adequate in some loca-
tions while even more intensive strategies are needed 
elsewhere. Learning how to identify the site characteris-
tics that might be matched to the most efficient quality 
improvement strategy is the overarching goal of this line 
of research.
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